The weight-loss drug Ozempic can help reduce stroke patients' risk of a heart attack or death, a new study says.

Stroke was the fourth leading cause of death in the US last year, accounting for 162,600 deaths, according to preliminary data.

In an analysis of more than 7,000 stroke survivors, those who were taking either a GLP1-receptor agonist or an SGLT2 inhibitor medication had a lower risk of a subsequent stroke, heart attack or death ...

GLP-1 receptor agonists and SGLT2 inhibitors, two classes of medications most commonly prescribed to treat Type 2 diabetes or ...

The researchers revealed that GLP-1 weight-loss drugs like Ozempic or SGLT2 diabetes medications like Jardiance or Farxiga ...

Sodium-glucose cotransporter 2 (SGLT2) inhibitors may protect the kidneys better than glucagon-like peptide 1 receptor ...

On Halloween, Lexicon was haunted again as an FDA advisory committee voted 11-3 to reject Zynquista as an accompanying ...

On Thursday, members of the Endocrinologic and Metabolic Drugs Advisory Committee will help the FDA decide whether the ...

Greatest increase in SGLT2 inhibitor use seen in subgroups with cardiovascular disease; greatest increase in GLP-1 RA for those with obesity.

Rate this content's potential impact on patient outcomes Submit Rating Thank you! Please share some more information on the ...

A recent case report highlights the importance of understanding the possibility of the development of Euglycemic diabetic ...

The use of SGLT2 inhibitors was associated with a significantly reduced risk for dementia and PD in patients with type 2 diabetes.